The advisory committee meeting date for the ANCHOR indication is now set.
An FDA panel will review Vascepa on Oct. 16, and expected combo data won't matter much.
AstraZeneca entered into an agreement with NGM Biopharmaceuticals, Inc. to develop candidates for type II diabetes and obesity.
This deal is in line with Teva's strategy of strengthening its position in the respiratory therapeutic area.
There's an investment opportunity, but it's going to take time to play out.